Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-07-02 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Pending Release of Shares from Voluntary Escrow 2 pages 148.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the pending release of shares from voluntary escrow related to a prior acquisition. It references ASX Listing Rule 3.10A and provides details about the number of shares and release date. The content is a regulatory announcement about share release, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is relatively short (5745 characters) and serves as a formal notification to the market about share escrow release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements that do not fit other specific categories.
2024-07-02 English
Ceasing to be a substantial holder from MUFG 627 pages 3.2MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 notice under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder' for Telix Pharmaceuticals Limited. It details changes in substantial shareholding, including dates, nature of changes, and associated parties. The document is a regulatory disclosure about shareholding changes, specifically a substantial holder ceasing to hold a relevant interest. It is not a financial report, earnings release, or management report. It is a formal notification of changes in major shareholding levels, consistent with the definition of Major Shareholding Notification (MRQ). The document length is substantial and contains detailed shareholding data, not just an announcement or certification, so it is not RNS or RPA. Therefore, the correct classification is MRQ with high confidence.
2024-07-02 English
Ceasing to be a substantial holder 2 pages 482.9KB
Major Shareholding Notification Classification · 100% confidence The document is a formal notice titled 'Notice of ceasing to be a substantial holder in Telix Pharmaceuticals Limited' and includes a Form 605 under the Corporations Act 2001 Section 671B. It details changes in relevant interests of substantial holders, specifically Jefferies LLC and associates, ceasing to be substantial holders due to termination of lock-up agreements related to a withdrawn US IPO. The document is a regulatory announcement about changes in significant share ownership levels, not a financial report or earnings release. It fits the definition of a Major Shareholding Notification (MRQ). The document length is 4596 characters, which is consistent with a detailed notice but not a full report. Therefore, the correct classification is MRQ with high confidence.
2024-07-02 English
Ceasing to be a substantial holder 4 pages 798.3KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and is a 'Notice of ceasing to be a substantial holder' under the Corporations Act 2001, Section 671B. It details changes in relevant interests of a substantial holder in voting securities, including dates, nature of changes, and securities affected. It includes annexures with detailed schedules of associated entities and securities lending agreements. The content is regulatory in nature, reporting changes in substantial shareholdings rather than financial results, management changes, or other report types. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document length and detail confirm it is not a brief announcement or a certification but a substantive notification. Therefore, the correct classification is MRQ with high confidence.
2024-07-01 English
Ceasing to be a substantial holder from MS 180 pages 930.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, specifically a "Notice of ceasing to be a substantial holder" for Telix Pharmaceuticals Limited. It details changes in substantial shareholdings by Morgan Stanley and its subsidiaries, including dates, nature of changes, and number of securities affected. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it focuses on shareholding changes rather than financial results or management changes.
2024-07-01 English
Ceasing to be a substantial holder 2 pages 192.8KB
Major Shareholding Notification Classification · 100% confidence The document is a 'Notice of ceasing to be a substantial holder' filed under the Corporations Act 2001 (Australia). It details changes in relevant interests of substantial holders in Telix Pharmaceuticals Limited, including dates and share quantities. The document includes a Form 605, which is a regulatory filing for substantial shareholding notifications. It is not a financial report, earnings release, or management report, but a formal notification of changes in significant share ownership levels. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is 4419 characters, which is consistent with a detailed notification rather than a brief announcement or a full report.
2024-07-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.